Home / Market News / $CLOV

$CLOV news and market catalysts

The 10 most recent market catalysts affecting $CLOV, each scored for sentiment and estimated stock impact. Sourced from SEC EDGAR filings and financial news, analysed automatically as they are published.

10 catalysts 5 high impact 8 bullish 0 bearish Healthcare
Nov 9, 2026 Corporate Catalyst Bullish Impact 85
Clover Health Reports Q3 2026 Financial Results and Raises Guidance
Clover Health's Q3 2026 results show substantial revenue growth of 53% year-over-year and a return to GAAP net income, indicating improved financial health and operational efficien…
Nov 5, 2026 Corporate Catalyst Bullish Impact 55
UBS Adjusts Price Target on Clover Health Investments to $5.50
UBS updated its price target for Clover Health Investments (CLOV) to $5.50 from $5.00, reflecting a modest upward revision in their valuation assessment. The firm maintained its 'N…
Nov 4, 2026 Corporate Catalyst Neutral Impact 85
Clover Health Reports Third Quarter 2026 Financial Results
Clover Health announced its Q3 2026 financial results, reporting revenue of $759.3 million, which significantly exceeded the FactSet consensus estimate of $740.1 million. This reve…
Oct 28, 2026 Corporate Catalyst Neutral Impact 65
Needham Initiates Coverage of Clover Health Investments with Buy Rating
Needham & Company has initiated coverage of Clover Health Investments (CLOV) with a 'Buy' rating and a $6 price target. This analyst action is significant as it represents new inst…
Aug 6, 2026 Corporate Catalyst Bullish Impact 85
Clover Health Investments shares are trading higher after the company reported better-than-expected Q2 financial results and raised its FY26 sales guidance above estimates.
This headline represents a significant corporate catalyst for Clover Health. The better-than-expected Q2 financial results suggest improved operational efficiency and potentially s…
Aug 5, 2026 Corporate Catalyst Bullish Impact 85
Clover Health Investments shares are trading higher after the company reported better-than-expected Q2 financial results and raised its FY26 sales guidance above estimates.
This headline represents a significant corporate catalyst for Clover Health. Better-than-expected financial results, especially coupled with raised future guidance, often signal a …
Aug 5, 2026 Corporate Catalyst Bullish Impact 75
Clover Health Investments Raises FY2026 Sales Guidance from $2.810B-$2.920B to $2.920B-$3.000B vs $2.910B Est
Clover Health Investments (CLOV) announced an upward revision to its FY2026 sales guidance, moving from $2.810B-$2.920B to $2.920B-$3.000B. This update is significant as it indicat…
Aug 5, 2026 Corporate Catalyst Bullish Impact 85
Clover Health Investments Q2 EPS $0.05 Beats $0.03 Estimate, Sales $743.167M Beat $728.267M Estimate
Clover Health Investments (CLOV) announced Q2 earnings of $0.05 per share, significantly surpassing the analyst consensus of $0.03, and marking a substantial turnaround from a loss…
Jul 21, 2026 Corporate Catalyst Bullish Impact 65
Clover Health Investments shares are trading higher after Canaccord Genuity maintained its Buy rating on the stock and raised its price target from $4.2 to $5.5.
The maintained 'Buy' rating and increased price target from a reputable firm like Canaccord Genuity acts as a positive catalyst for Clover Health. This signals to the market that t…
Jul 21, 2026 Corporate Catalyst Bullish Impact 55
Canaccord Genuity Maintains Buy on Clover Health Investments, Raises Price Target to $5.5
Canaccord Genuity's analyst Richard Close maintained a 'Buy' rating for Clover Health Investments (CLOV) and raised the price target from $4.2 to $5.5. This action signals increase…
Join the waitlist for full signal validation →

Not financial advice. AI-generated analysis for informational purposes only. Tradow AI LLC is not a registered investment adviser.